<DOC>
	<DOCNO>NCT00093561</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain substance try prevent development recurrence cancer . The dietary supplement lycopene may prevent development prostate cancer . PURPOSE : This phase I trial study side effect best dose lycopene prevent prostate cancer healthy participant .</brief_summary>
	<brief_title>Lycopene Preventing Prostate Cancer Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity safety lycopene supplementation chemoprevention prostate cancer healthy participant . - Determine pharmacokinetics agent participant . - Determine dose range agent participant . OUTLINE : This dose-escalation study . Participants ingest single-dose oral lycopene maximum 15 minute day 1 . Cohorts 5 participant receive escalate dos lycopene maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 participant experience dose-limiting toxicity . Participants evaluate periodically 28 day . PROJECTED ACCRUAL : A total 25 participant accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lycopene</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant good medical condition No chronic medical condition No regular use prescription medication No evidence psychiatric disorder Nonsmoker Former smoker allow provide smoke within past 3 month No history alcohol abuse Serum lycopene concentration &lt; 700 nM PATIENT CHARACTERISTICS : Age 18 45 Performance status Karnofsky 100 % Life expectancy Not specify Hematopoietic Hemoglobin ≥ 13.0 g/dL WBC ≥ 4,000/mm^3 Platelet count 150,000400,000/mm^3 Hepatic AST ALT ≤ 75 U/L Bilirubin ≤ 2.0 mg/dL No liver disease Renal Creatinine ≤ 1.5 mg/dL No renal disease Cardiovascular No cardiovascular disease No abnormal EKG Other Within 15 % ideal body weight No history gastrointestinal malabsorption condition would preclude drug absorption No alcohol consumption within past 72 hour No allergy tomatobased product No history cancer No diabetes mellitus No illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 4 week since prior experimental drug More 14 day since prior prescription drug No concurrent participation another experimental trial No concurrent prescription drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>